KRBPQ — Kiromic Biopharma Balance Sheet
0.000.00%
- $0.09m
- $12.61m
Annual balance sheet for Kiromic Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 10.2 | 25.4 | 0.645 | 3.2 | 1.14 |
Net Total Accounts Receivable | |||||
Net Total Receivables | — | 0.016 | 0 | — | — |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 10.7 | 27.1 | 1.69 | 4.43 | 3.3 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 2.07 | 3.63 | 10.3 | 7.72 | 5.22 |
Other Long Term Assets | |||||
Total Assets | 12.8 | 30.7 | 12 | 12.2 | 8.54 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Current Liabilities | 1.47 | 3.41 | 13.3 | 20.4 | 20.9 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 1.47 | 3.41 | 17.7 | 21.3 | 21.1 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 11.4 | 27.3 | -5.77 | -9.12 | -12.6 |
Total Liabilities & Shareholders' Equity | 12.8 | 30.7 | 12 | 12.2 | 8.54 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |